BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 14523586)

  • 1. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning.
    Zanzonico P; O'Donoghue J; Chapman JD; Schneider R; Cai S; Larson S; Wen B; Chen Y; Finn R; Ruan S; Gerweck L; Humm J; Ling C
    Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):117-28. PubMed ID: 14523586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort.
    Riedl CC; Brader P; Zanzonico P; Reid V; Woo Y; Wen B; Ling CC; Hricak H; Fong Y; Humm JL
    Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):39-46. PubMed ID: 17786438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.
    Piert M; Machulla HJ; Picchio M; Reischl G; Ziegler S; Kumar P; Wester HJ; Beck R; McEwan AJ; Wiebe LI; Schwaiger M
    J Nucl Med; 2005 Jan; 46(1):106-13. PubMed ID: 15632040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of [
    Nakata N; Kiriu M; Okumura Y; Zhao S; Nishijima KI; Shiga T; Tamaki N; Kuge Y; Matsumoto H
    Nucl Med Biol; 2019 Mar; 70():39-45. PubMed ID: 30836255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
    O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma.
    Grönroos T; Bentzen L; Marjamäki P; Murata R; Horsman MR; Keiding S; Eskola O; Haaparanta M; Minn H; Solin O
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):513-20. PubMed ID: 14722675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution, pharmacokinetics and PET imaging of [(18)F]FMISO, [(18)F]FDG and [(18)F]FAc in a sarcoma- and inflammation-bearing mouse model.
    Liu RS; Chou TK; Chang CH; Wu CY; Chang CW; Chang TJ; Wang SJ; Lin WJ; Wang HE
    Nucl Med Biol; 2009 Apr; 36(3):305-12. PubMed ID: 19324276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia.
    Gagel B; Reinartz P; Dimartino E; Zimny M; Pinkawa M; Maneschi P; Stanzel S; Hamacher K; Coenen HH; Westhofen M; Büll U; Eble MJ
    Strahlenther Onkol; 2004 Oct; 180(10):616-22. PubMed ID: 15480509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO.
    Chen L; Zhang Z; Kolb HC; Walsh JC; Zhang J; Guan Y
    Nucl Med Commun; 2012 Oct; 33(10):1096-102. PubMed ID: 22836736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.
    Rajendran JG; Wilson DC; Conrad EU; Peterson LM; Bruckner JD; Rasey JS; Chin LK; Hofstrand PD; Grierson JR; Eary JF; Krohn KA
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):695-704. PubMed ID: 12632200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.
    Rasey JS; Hofstrand PD; Chin LK; Tewson TJ
    J Nucl Med; 1999 Jun; 40(6):1072-9. PubMed ID: 10452326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results.
    Reischl G; Dorow DS; Cullinane C; Katsifis A; Roselt P; Binns D; Hicks RJ
    J Pharm Pharm Sci; 2007; 10(2):203-11. PubMed ID: 17706178
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Yu W; Qiao F; Su X; Zhang D; Wang H; Jiang J; Xu H
    Biomed Pharmacother; 2019 Nov; 119():109454. PubMed ID: 31526971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode Po2 measurements in murine tumors.
    Sørensen M; Horsman MR; Cumming P; Munk OL; Keiding S
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):854-61. PubMed ID: 15936570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of three
    Dos Santos SN; Wuest M; Jans HS; Woodfield J; Nario AP; Krys D; Dufour J; Glubrecht D; Bergman C; Bernardes ES; Wuest F
    Nucl Med Biol; 2023; 124-125():108383. PubMed ID: 37651917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
    Dence CS; Ponde DE; Welch MJ; Lewis JS
    Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic Analysis of Dynamic
    Schwartz J; Grkovski M; Rimner A; Schöder H; Zanzonico PB; Carlin SD; Staton KD; Humm JL; Nehmeh SA
    J Nucl Med; 2017 Jun; 58(6):911-919. PubMed ID: 28232611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Bioevaluation of Novel [
    Yang X; Wang F; Zhu H; Yang Z; Chu T
    Mol Pharm; 2019 May; 16(5):2118-2128. PubMed ID: 30964298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of the hypoxia PET tracers [¹⁸F]HX4, [¹⁸F]FAZA, and [¹⁸F]FMISO in a preclinical tumor model.
    Peeters SG; Zegers CM; Lieuwes NG; van Elmpt W; Eriksson J; van Dongen GA; Dubois L; Lambin P
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):351-9. PubMed ID: 25491505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)- N-(3,3,3-[(18)F]trifluoropropyl)acetamide, [(18)F]EF3.
    Mahy P; De Bast M; Leveque PH; Gillart J; Labar D; Marchand J; Gregoire V
    Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1263-72. PubMed ID: 15197503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.